Recent Updates
Recently added Catalysts

Imeroprubart

Phase 2

Chronic Inflammatory Demyelinating Polyneuropathy | Small molecule | Neurology |Immunovant, Inc.|Last Updated: Jun 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment162
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07032662Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE2 RECRUITING 162 — — Mar 18, 2025May 1, 2030Jun 8, 2026135 United States, Argentina +28
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Proportion of participants remaining Relapse-free by Week 24
Baseline, Week 24

Relapse is defined as a worsening (increase) of ≥ 1 point on the adjusted inflammatory neuropathy cause and treatment (aINCAT) score at any time point relative to Period 1 Baseline.

Secondary Endpoints
Change from baseline to Week 24 in Inflammatory Rasch-Built Overall Disability Scale (I-RODS)
Baseline and Up to Week 24
Change from baseline to Week 24 in Mean Grip Strength in the dominant hand
Baseline and Up to Week 24
Change from baseline to Week 24 in Medical Research Council Sum Score (MRC-SS)
Baseline and Up to Week 24
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ImeroprubartEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
ImeroprubartDRUGDose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
PlaceboDRUGMatching placebo SC QW for 24 weeks (Period 1)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites135

Inclusion Criteria: * Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP. * Have electrodiagnostic test...

Countries:United StatesArgentinaAustraliaAustriaBelgiumBosnia and HerzegovinaBrazilBulgariaColombiaDenmarkEstoniaFinlandGermanyGreeceHungaryIrelandItalyMexicoNetherlandsNorwayPeruPolandPortugalRomaniaSerbiaSlovakiaSloveniaSpainTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 8, 2026NCT07032662lastUpdatePostDate: changed
LOWJun 8, 2026NCT07032662lastUpdatePostDate: changed
LOWJun 8, 2026NCT07032662lastUpdatePostDate: changed
MEDIUMMay 26, 2026NCT07032662primaryCompletionDate: changed
LOWMay 24, 2026NCT07032662studyFirstPostDate: changed